Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Vascular Disease Clear all
Terminated Phase 3 Interventional

Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation

NCT00060450
View directory record Official record
Conditions
Ischemia-Reperfusion Injury
Interventions
nitric oxide for inhalation, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Not applicable Interventional Results available

VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial

NCT01112917
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
VenaTech Convertible Vena Cava Filter, Vena Cava Filter Conversion
Device · Procedure
Lead sponsor
B. Braun Interventional Systems, Inc
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Miami, Florida • Chicago, Illinois • Hinsdale, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 21, 2026, 9:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Physical Rehabilitation of COVID-19 Survivors by Heat Therapy

NCT04673318
View directory record Official record
Conditions
Covid19, Physical Disability
Interventions
heat therapy, exercise training
Behavioral
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
55 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Not applicable Interventional

A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter

NCT00654979
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
SafeFlo IVC Filter
Device
Lead sponsor
RMT Medical Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Teaneck, New Jersey • Manhattan, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jul 21, 2026, 9:21 AM EDT
Enrolling by invitation No phase listed Observational

Genetic Markers of Patients With History of Pulmonary Embolism Post Total Joint Arthroplasty

NCT03275610
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Blood sample
Genetic
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 21, 2026, 9:21 AM EDT
Recruiting Phase 2 Interventional

Repetitive Transcranial Magnetic Stimulation, a Form of Non-invasive Brain Stimulation, as a Possible Treatment for Post-stroke Fatigue.

NCT05584124
View directory record Official record
Conditions
Stroke, Stroke, Chronic, Fatigue
Interventions
High frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
34 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 9:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

NCT00350844
View directory record Official record
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Hydroxyurea
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jul 21, 2026, 9:21 AM EDT
Completed No phase listed Observational

Graded TTCE for Post-Embolization PAVM Monitoring

NCT02936349
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Transthoracic Contrast Echocardiogram
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 3 Interventional

A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities

NCT00935077
View directory record Official record
Conditions
Hypertension, Asthma
Interventions
PPCM Asthma, 24 Month PPCM BP, 9 Month PPCM BP
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
1,441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
28
States / cities
San Diego, California • Hartford, Connecticut • Gainesville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Jul 21, 2026, 9:21 AM EDT
Terminated Phase 2 Interventional Results available

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

NCT01409031
View directory record Official record
Conditions
Persistent Pulmonary Hypertension, Respiratory Failure
Interventions
Intravenous Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 21, 2026, 9:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Factors for Venous Thromboembolism

NCT00018772
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jul 21, 2026, 9:21 AM EDT
Terminated No phase listed Observational

Resynchronization of Left Ventricular Contraction After Reimplantation of Anomalous Left Coronary Artery

NCT00268112
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

NCT04283994
View directory record Official record
Conditions
Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions
Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 21, 2026, 9:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

NCT05366881
View directory record Official record
Conditions
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Adela, Inc
Industry
Eligibility
40 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jul 21, 2026, 9:21 AM EDT
Completed No phase listed Observational

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood

NCT04401436
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 3 Interventional

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

NCT00091598
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
44
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

NCT00439777
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397
View directory record Official record
Conditions
Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
Interventions
CC-223
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 4 Interventional

Natrecor for Pulmonary Hypertension in Lung Transplants

NCT00205426
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Natrecor
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Not applicable Interventional Results available

Cutting Balloon Study

NCT01205568
View directory record Official record
Conditions
Pulmonary Artery Stenosis
Interventions
Transcatheter Cutting Balloon therapy, High Pressure Balloon Angioplasty
Device · Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
San Francisco, California • Boston, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Jul 21, 2026, 9:21 AM EDT
Withdrawn Phase 4 Interventional

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

NCT00625079
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
sildenafil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 21, 2026, 9:21 AM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 21, 2026, 9:21 AM EDT